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Introduction 
Neurofibromatosis type 1 (NF1) is an autosomal 
dominant disorder with a prevalence of 
approximately 1 in 3,000 [1]. Neurofibromatosis 
type 1 results from germline mutations in the NF1 
gene encoding the neurofibromin protein. 
Neurofibromin is a negative regulator of neural 
crest-derived tissue growth and differentiation. In 
this regard, NF1 mutations have been associated 
with an increased risk of neural crest tumors, 
including malignant peripheral neural sheath 
tumors (MPNSTs), peripheral nerve sheath tumors 
(neurofibromas), and pheochromocytomas. 
Although melanocytes are also of neural crest 
origin and the NF1 gene is a frequently mutated 
gene in sporadic melanoma [2-3], there is a lack 
of convincing evidence for an increased risk of 
malignant melanoma in patients with NF1. Prior 
case reports have suggested a relationship 
between melanoma and NF1, but larger 
population-based studies have not provided clear 
evidence for an association [4-13]. Given the small 
number of studies focused on this cancer type in 
NF1, we sought to evaluate the risk of melanoma 
in people with NF1. 
Abstract 
Background: Neurofibromatosis type 1 (NF1) is a 
cancer syndrome associated with many different 
cancer types. There are limited studies examining 
melanoma risk in this population. 
Objective: To identify melanoma cases in NF1 
patients and compare melanoma incidence rates 
relative to a general population sample. 
Methods: A retrospective single institution case 
review of 857 NF1 patients (seen from 7/1997 to 
7/2017) was conducted. We calculated age- and 
calendar period-adjusted standardized incidence 
ratios (SIRs) for white patients >20 years old 
overall (N=282) and for females (N=156) at their 
last visit date. We obtained general population 
melanoma reference rates from the Surveillance, 
Epidemiology, and End Results (SEER) 9 database. 
Results: Among 857 patients, 52.2% were female, 
54% were <20 (mean±sd=10.9±4.6) years old, and 
46% were >20 (40.4±14.9) years old at their last 
visit date. One white female patient had a 
malignant melanoma diagnosed at 47 years old. 
The adjusted SIR was 0.97 (95% CI 0.05-4.78) 
overall (N=282) and 1.62 (95% CI 0.08-7.98) for 
females (N=156). 
Conclusions: We did not find statistical evidence 
for an increased melanoma risk in adults with NF1. 
However, additional large studies are warranted to 
clarify whether melanoma risk is increased in NF1 
patients. 
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Methods 
A retrospective case review was conducted to 
identify individuals with NF1 and melanoma 
following approval by the Washington University 
Institutional Review Board spanning visits 
between July 1997 and July 2017. We used a 
previously compiled neurofibromatosis patient 
medical record registry [14-15] as the initial 
patient cohort and added additional patients seen 
during the expanded study period. We used a 
REDCap database 
(https://projectredcap.org/software/) to capture 
all study data. Patient records, including physician 
notes (history and physical), patient 
questionnaires, anesthesia records, outpatient 
surgery and pre-hospitalization forms, imaging 
records, administrative notes, and inpatient 
records, were examined for a documented NF1 
diagnosis; patients without a documented NF1 
diagnosis were excluded from analysis (N=130). 
Patient records were also examined for age, sex, 
race/ethnicity, and reported melanoma or 
melanoma in situ diagnoses along with the age at 
diagnosis. For patients with a diagnosis of 
melanoma, Breslow depth, stage of disease, 
histological subtype, and clinical course were 
noted. 
To compare risk of melanoma in our NF1 cohort 
to the general population, age and calendar year 
standardized incidence ratios (SIRs) were 
calculated. For this calculation, we only included 
individuals with a reported race of white and who 
were >20 years old at their last visit (N=282), since 
melanoma is extremely rare in individuals <20 
years of age and in those who are non-white. In 
addition, we did not observe any melanoma cases 
in these groups. General population melanoma 
age-adjusted incidence rates were obtained by 
sex, age group (20-24, 25-29, 30-34, 35-39, 40-44, 
50-54, 55-59, 60-64, 65-69, 70-74, 75-79, and >80 
years), and calendar period (1973-1977, 1978-
1982, 1983-1987, 1988-1992, 1993-1997, 1998-
2002, 2003-2007, 2008-2012, and 2013-2014) 
from the Surveillance, Epidemiology, and End 
Results (SEER) 9 [16] database using SEER*Stat 
software [17] with selection criteria of white race 
using the “Race recode (White, Black, Other)” 
variable and “Melanoma of the Skin” using the 
“Site recode ICD-O-3/WHO 2008” variable [16]. 
We calculated age group and calendar period 
specific person-years at risk for each subject as 
the person-time contributed to a specific age 
group calendar period interval starting at age 20 
years old using Statistical Analysis Software 
(Version 9.4, Cary, NC). Person-time was censored 
in a specific age group calendar period interval if 
the date of melanoma diagnosis, death, or last 
follow-up as defined by the visit date of the last 
record occurred during that interval. The total 
person-years at risk for each sex in each age 
group and calendar year interval was multiplied 
by the corresponding age group and calendar 
period sex-specific incidence rate from SEER to 
generate the expected number of cases for that 
interval. This number was then summed across 
each age group and calendar year interval to yield 
the total expected number of melanoma cases in 
our NF1 cohort for each sex. Finally, the expected 
Table 1. Baseline characteristics of study patients. 
Variable N (%) 
Age category 
     < 18 years 432 (50.4) 
     ≥ 18 years 425 (49.6) 
Sex 
     Male 410 (47.8) 
     Female 447 (52.2) 
Race/Ethnicity 
     White 632 (73.8) 
     Black 184 (21.5) 
     Hispanic 11 (1.3) 
     Asian 10 (1.2) 
     Other/Unknown 20 (2.2) 
Melanoma diagnoses 
     <18 years 0 (0) 
     ≥18 years 1 (0.1) 
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number for both sexes summed and for females 
was divided by the observed number of cases, 
respectively, to calculate SIRs. Fisher’s exact test P 
values and 95% CIs for the SIRs were calculated 
using OpenEpi software 
(http://www.openepi.com/SMR/SMR.htm). A post 
hoc power calculation was performed in R 
software version 3.5.0 using the function 
power.smr.test referenced at 
https://rdrr.io/github/clayford/bme/man/power.s
mr.test.html. 
 
Results 
A total of 857 patients had a medical record-
verified diagnosis of NF1. There were more 
females than males in the cohort with 447 female 
(52.2%) and 410 male (47.8%) patients. Four 
hundred sixty-two (53.9%) patients were <20 
years, whereas the remainder were >20 years old 
on the last visit date during the study period. The  
mean age for those <20 years was 10.9±4.6 years 
(range 0-19 years) whereas for those >20 years 
was 40.4±14.9 years (range 20-86 years). The 
distribution of reported race/ethnicity was 73.6% 
white (N=632), 21.5% black (N=184), 1.3% 
hispanic (N=11), 1.2% asian (N=10), and 2.3% 
other or unknown (N=20). A total of 282 patients 
with NF1 and reported white race who were >20 
years old (mean±sd=39.4±14.3, range 20-81 
years) on their last visit date were included in the 
SIR calculation. They had a similar sex distribution 
as the overall group with 156 (55.3%) female and 
126 (44.7%) male patients (Table 1). 
We identified one individual with a malignant 
melanoma diagnosis in their record among the 
857 patients. The patient was a 47-year-old white 
woman with a history of NF1 diagnosed in 
childhood, complicated by pheochromocytoma 
status post right adrenalectomy and a right above 
the knee amputation due to NF1-associated  
Table 2. Literature review of the association between NF1 and melanoma from studies that calculated prevalence and risk 
estimates.  
Authors Publication findings Prevalence Risk estimate 
Brasfield & Das 
Gupta [4] 
Six melanomas in 110 patients, 3 from giant congenital 
nevi 
5.5%  
Guillot et al. [5] 
Eleven patients with melanoma: 3 melanomas in 671 
patients at 4 centers with NF1 and melanoma registries 
and 8 melanomas in an unknown number of patients at 
an additional 6 centers 
0.45%  
Hope et al. [6] No melanomas identified in 395 patients 0%  
Knight et al. [7] One melanoma in 45 patients 2.2%  
Rasmussen et al. [8]  
Melanoma listed as cause of death in 12 of 3770 NF1 
patients compared to cause of death on death 
certificates in the general population 
0.32% 
PMR 0.52  
(95% CI 0.27-0.90) 
Rubenstein et al. [9] Four melanomas in 791 patients 0.51%  
Seminog et al. [10] 
Nineteen melanomas in 6739 NF1 patients compared to 
rates of melanoma in a linked data set of hospital 
admissions in England 
0.28% 
RR 3.60  
(95% CI 2.20–5.60) 
Sorensen et al. [11] One melanoma in 212 patients 0.47%  
Uusitalo et al. [12] 
Three melanomas in 1404 NF1 patients compared to 
rates of melanoma in an age, calendar and gender 
adjusted Finish cohort 
0.21% 
SIR 1.58  
(95% CI 0.32-4.60) 
Zoller et al. [13] One melanoma in 70 patients 1.4%  
PMR = proportional mortality ratio, CI = confidence interval, RR = relative risk, SIR = standardized incidence ratio.  
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skeletal deformities. She had no history of 
dysplastic nevi. She initially presented with 
abdominal pain and vomiting in the emergency 
room and a CT abdomen and pelvis showed 
extensive tumors throughout her body including 
in her lungs, liver, kidneys, and lymph nodes. A 
biopsy of a right inguinal lymph node was 
diagnostic for metastatic melanoma with 
unknown primary, and immunohistochemistry 
was negative for the BRAFV600 mutation. She was 
started on ipilimumab and got four rounds of 
therapy before dying from respiratory failure two 
months after her initial diagnosis. 
The age, sex, and calendar year adjusted SIR 
among the 282 subjects included in the SIR 
calculation was 0.97 (95% CI 0.05-4.78, P=0.55). 
For females, the SIR was 1.62 (95% CI 0.08-7.98, 
P=0.92). 
 
Discussion 
The findings described in our study add to 
previous reports, with no statistically significant 
evidence for an increased risk of melanoma in the 
NF1 population. Although there have been many 
case reports and small case series postulating a 
link between NF1 and melanoma, larger studies 
have not consistently revealed statistically 
significant evidence for an increased melanoma 
risk in adults with NF1. Seminog et al. [10] found 
an increased melanoma risk in NF1 patients, with 
19 melanoma cases in 6,739 NF1 patients 
(prevalence 0.28%) and an age, sex, and calendar 
year adjusted increased relative risk of 3.6 (95% CI 
2.2-5.6) versus the general population. However, 
a large Finnish study by Uusitalo et al. [12] did not 
find statistical evidence for an increased incidence 
of melanoma, identifying three patients with 
melanoma out of 1,404 NF1 patients (prevalence 
0.21%), with an age, sex, and calendar-year 
adjusted SIR of 1.58 (95% CI 0.32-4.60, P=0.67). 
Other studies noted a prevalence of melanoma in 
smaller NF1 cohorts ranging from 0-5.5% [4-13]. 
An increased melanoma risk in NF1 patients is 
plausible given that NF1 mutations are found in a 
subset of sporadic melanomas, especially those 
associated with chronically sun-damaged skin, 
older age, desmoplastic type, and higher 
mutational burden [18-22]. Additionally, NF1 loss 
in melanoma has been associated with other 
mutations in the RAS pathway, including RAS p21 
protein activator 2 (RASA2), PTPN11, SOS1, RAF1, 
and SPRED1 [17]. This finding suggests that 
multiple mutations in the RAS pathway may be 
necessary to progress to malignant melanoma 
and that the NF1 mutation alone is not sufficient 
by itself to cause melanoma. 
A possible reason for a lack of strong evidence for 
an increased melanoma risk in NF1 may reflect 
decreased sun exposure in this patient 
population. Although patients with NF1 are not 
usually counseled to avoid sunlight, they may do 
so because of physical and mental disabilities as 
well as social isolation. Johnson et al. [23] found 
that children with NF1 without orthopedic 
impairments had decreased participation in a 
variety of physical and social activities. Feelings of 
loneliness [24] and social self-consciousness [25] 
have also been reported in older individuals with 
NF1. It is possible that the social isolation 
experienced by many people with NF1 may result 
in decreased sun exposure, offsetting any 
increased risk for melanoma that would be 
expected to occur as a result of a germline NF1 
mutation. Further research is needed to test this 
hypothesis.  
The current study has some limitations. First, there 
was a large proportion of pediatric patients in the 
cohort, whereas melanoma predominantly affects 
older individuals. However, given that increased 
malignancy risk of NF1 is higher at younger ages,  
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this study is still relevant in showing no cases of 
melanoma in a pediatric population. Second, 
although this is one of the larger studies on this 
topic, it represents a single institution study that 
is underpowered. Given our relatively small 
sample size and confidence intervals for SIRs 
overall and for females that are compatible with 
larger risks, we cannot exclude the possibility of 
an increased risk for melanoma in the NF1 
population. A post hoc power calculation 
indicated 80% power to detect an SIR of 8, which 
would mark a strongly increased risk of 
melanoma. Third, owing to the retrospective 
nature of the study, the dataset may be 
incomplete if patients were seen outside our 
institution. However, as a tertiary care center with  
a large oncology outpatient center, it can be 
presumed that patients diagnosed with invasive 
melanoma at outside institutions would be 
referred back to our institution in some capacity 
for surgery, oncology, or long-term follow up in a 
high-risk skin cancer patient. 
 
Conclusion 
The findings reported herein contribute to the 
existing literature on melanoma risk in NF1 
patients, which is important when counseling 
patients with this disorder. 
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